Literature DB >> 19999392

Concurrence of multiple myeloma and idiopathic erythrocytosis.

H Chang1, L Y Shih.   

Abstract

The association of erythrocytosis and multiple myeloma is rare. We encountered a 76-year-old male patient with erythrocytosis followed by the diagnosis of multiple myeloma 8 months later. Related laboratory examinations revealed absolute erythrocytosis, normal oxygen saturation and erythropoietin (EPO) levels, the absence of endogenous erythroid colony (EEC) and JAK2-V617F mutations. The diagnosis of idiopathic erythrocytosis (IE), instead of polycythemic vera (PV), was made. In the literature, about 20 cases of erythrocytosis associated with myeloma can be found. Based on elevated EPO levels, 2 of such cases should be considered secondary erythrocytosis while others are reported as PV. None of them is considered to be have idiopathic erythrocytosis. Our present case is the first one with multiple myeloma developing in a patient with the diagnosis well established by extensive laboratory workup. The pathogenic role of these two entities remains to be established.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19999392     DOI: 10.1179/acb.2009.071

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  4 in total

1.  The JAK2 V617F Mutation in Plasma Cell Neoplasms with Co-existing Erythrocytosis.

Authors:  Stephen E Langabeer
Journal:  J Clin Diagn Res       Date:  2015-12-01

2.  Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review.

Authors:  Jinning Shi; Ying Ni; Jianyong Li; Hairong Qiu; Kourong Miao
Journal:  Oncol Lett       Date:  2015-03-16       Impact factor: 2.967

3.  Polycythaemia: an unusual presentation of multiple myeloma.

Authors:  Elaine J Hutchison; Josephine A Taverna; Qi Yu; Andrew M Yeager
Journal:  BMJ Case Rep       Date:  2016-09-20

4.  Multiple myeloma and primary erythrocytosis in a dog.

Authors:  Marianna Ricci; Giulia De Feo; Martin Konar; George Lubas
Journal:  Can Vet J       Date:  2021-08       Impact factor: 1.008

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.